Vetter Success Story

Our sustainability report, which was first published in 2022, is comprised of 82 pages and offers a detailed overview of all actions and a strategic perspective on Vetter's ecological, economic and social goals that should be reached by 2029.

After one and a half years of renovation, Vetter obtained the operating license for its new clinical production facility Vetter Development Service Rankweil in Austria's Vorarlberg region at the end of the year. The production site has been supporting international customers ever since during the important phase of process development and clinical filling of innovative APIs. 

This achievement highlights our commitment to protecting our climate and environment, and reflects an important element of our responsible corporate governance.

Our Center for Visual Inspection and Logistics wins the renowned Facility the the Year Award (FOYA), in the category “Facility of the Future.” The International Society for Pharmaceutical Engineering (ISPE) is impressed by the intelligent combination of location design, state-of-the-art technology, and innovative processes.

With the establishment of aregional office in South Korea, Vetter underscores its commitment to the Asia Pacific market. The new office footprint better positions us to both support existing business in South Korea and help new local and global customers meet stringent development, manufacturing, and packaging requirements of their injectable drugs.

Expansion of our Ravensbug Schuetzenstrasse building helps us meet growing customer demand for drug development support, as well as our own need for enhanced IT systems.

A new Vetter business entity in Tokyo underscores Japan’s importance to our business. As the second largest pharmaceutical market, Japan is home to a number of leading global companies with promising injectable products in their pipelines. Our new regional office supports customer relations and the development of new business within Japan.

Vetter opens its first Asia-Pacific office to boost our regional presence and tap Asia’s rapidly growing healthcare market. The new office supports both customer relations and the development of new business.

This year marks the first of many clinical-to-commercial product transfers from the US to Germany, providing further proof of our versatile single-source manufacturing services.

In many ways, the site’s optimized operations are an investment in the future: they use a variety of renewable power sources, including energy from both photovoltaic cells and biogas.

Now, Vetter can provide direct regional support to North American customers who need early-phase, cGMP-compliant aseptic filling of vials, syringes, and cartridges.

Our North American sales office relocates from Yardley, Pennsylvania, to a community outside Chicago, Illinois. Our subsidiary settles in the suburb of Skokie, future home of our first US production site: a new facility dedicated to early-phase clinical development. Short commutes and a faster, more direct information exchange strengthens our partnership with regional customers.

In the fall, Vetter opens its Ravensburg Vetter South site, including our new secondary packaging facility, VSP.

This new direction brings investment in new facilities, like Ravensburg Vetter South (RVS), as well as expansion of existing sites and implementation of new operational technology and quality assurance systems.

Two years later, Vetter uses robots in the aseptic production process for the first time ever, setting a new quality standard for parenteral product manufacturing. In 1996, production of the Vetter Lyo-Ject® dual chamber syringe is fully automated at our manufacturing facility in Langenargen.

Vetter Pharma-Turm Inc. is founded in New Jersey, USA, demonstrating Vetter’s growing international focus. In 1984, the prototype for the dual-chamber Vetter Lyo-Ject® syringe is presented worldwide.

Our company begins sealing in reduced-particle manufacturing areas. Helmut Vetter introduces the concept of the prefilled syringe, which becomes the focus of the manufacturing portfolio in the late 70s.